Cryosurgical Ablation of Liver Tumors Policy
Policy governs coverage determination for cryosurgical ablation (open, laparoscopic, percutaneous) of primary or metastatic liver tumors for commercial and Medicare products, including inpatient preauthorization requirements and coding guidance. It states the technology is investigational and outpatient procedures are not covered for specified products.
Annual policy review November 2025: policy updated with literature review through July 29, 2025; reference added; guidelines updated. Policy statement unchanged.
Coverage Summary & Determination
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.